Larimar Therapeutics (LRMR) Competitors $3.14 +0.03 (+0.96%) Closing price 07/3/2025 02:54 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. CRON, XERS, PHAR, REPL, VIR, GYRE, PHAT, NUVB, DNA, and DAWNShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Cronos Group (CRON), Xeris Biopharma (XERS), Pharming Group (PHAR), Replimune Group (REPL), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Cronos Group Xeris Biopharma Pharming Group Replimune Group Vir Biotechnology Gyre Therapeutics Phathom Pharmaceuticals Nuvation Bio Ginkgo Bioworks Day One Biopharmaceuticals Larimar Therapeutics (NASDAQ:LRMR) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Is LRMR or CRON more profitable? Cronos Group has a net margin of 39.69% compared to Larimar Therapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -52.48% -46.08% Cronos Group 39.69%-0.07%-0.07% Which has more risk and volatility, LRMR or CRON? Larimar Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Does the media refer more to LRMR or CRON? In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 2 articles in the media. Larimar Therapeutics' average media sentiment score of 0.83 beat Cronos Group's score of 0.46 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in LRMR or CRON? 91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 6.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend LRMR or CRON? Larimar Therapeutics presently has a consensus price target of $18.50, indicating a potential upside of 489.17%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, LRMR or CRON? Cronos Group has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.49-2.11Cronos Group$117.61M6.69$41.08M$0.1315.69 SummaryCronos Group beats Larimar Therapeutics on 9 of the 15 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$204.89M$2.43B$5.56B$9.04BDividend YieldN/A1.78%5.22%3.99%P/E Ratio-2.119.0227.6520.23Price / SalesN/A680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book1.174.558.035.65Net Income-$80.60M$31.26M$3.18B$249.15M7 Day Performance8.65%2.98%2.88%2.91%1 Month Performance17.16%3.46%1.67%4.11%1 Year Performance-58.63%0.77%34.39%20.98% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics1.942 of 5 stars$3.14+1.0%$18.50+489.2%-58.6%$204.89MN/A-2.1130CRONCronos Group2.0073 of 5 stars$1.91+0.5%N/A-8.5%$736.65M$117.61M14.69450News CoverageXERSXeris Biopharma3.6202 of 5 stars$4.67-0.6%$6.25+33.8%+125.4%$730.30M$203.07M-15.57290PHARPharming Group2.8916 of 5 stars$10.68-2.9%$30.00+181.0%+27.7%$726.29M$297.20M-53.38280Positive NewsGap DownHigh Trading VolumeREPLReplimune Group4.1737 of 5 stars$9.29-0.4%$20.83+124.3%+16.5%$719.22MN/A-3.03210News CoverageAnalyst ForecastVIRVir Biotechnology3.2017 of 5 stars$5.04-2.5%$32.86+551.9%-35.6%$696.73M$74.21M-1.19580News CoveragePositive NewsInsider TradeGYREGyre Therapeutics0.0779 of 5 stars$7.35-0.9%N/A-34.5%$689.14M$105.76M367.6840PHATPhathom Pharmaceuticals3.5903 of 5 stars$9.59-1.5%$17.50+82.5%-14.9%$669.48M$55.25M-1.83110NUVBNuvation Bio3.4373 of 5 stars$1.96+1.3%$7.17+266.6%-31.2%$665.21M$7.87M-0.8360High Trading VolumeDNAGinkgo Bioworks1.0991 of 5 stars$11.29+19.3%$5.77-48.9%N/A$660.80M$227.04M-1.23640Gap UpDAWNDay One Biopharmaceuticals1.7011 of 5 stars$6.50+0.5%$30.57+370.3%-50.4%$658.84M$131.16M-9.1560Upcoming Earnings Related Companies and Tools Related Companies Cronos Group Alternatives Xeris Biopharma Alternatives Pharming Group Alternatives Replimune Group Alternatives Vir Biotechnology Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Nuvation Bio Alternatives Ginkgo Bioworks Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
